Evofem Biosciences Inc
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recur… Read more
Evofem Biosciences Inc (EVFM) - Total Liabilities
Latest total liabilities as of December 2024: $95.05 Million USD
Based on the latest financial reports, Evofem Biosciences Inc (EVFM) has total liabilities worth $95.05 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Evofem Biosciences Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Evofem Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Evofem Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Evofem Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Meiwu Technology Co Ltd
NASDAQ:WNW
|
USA | $1.73 Million |
|
ABERCROMBIE FTCH-A
BE:AFT
|
Germany | €1.83 Billion |
|
Trenchant Technologies Capital Corp.
PINK:AITTF
|
USA | $2.17 Million |
|
ExpreS2ion Biotech Holding AB (publ)
F:5JD0
|
Germany | €28.47 Million |
|
Cleantech Power Corp.
PINK:PWWRF
|
USA | $1.61 Million |
|
Nuzee Inc
NASDAQ:NUZE
|
USA | $2.94 Million |
|
Cascadero Copper Corporation
PINK:CCEDF
|
USA | $561.17K |
|
Acdc Metals Ltd
AU:ADC
|
Australia | AU$375.16K |
Liability Composition Analysis (2012–2024)
This chart breaks down Evofem Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evofem Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evofem Biosciences Inc (2012–2024)
The table below shows the annual total liabilities of Evofem Biosciences Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $95.05 Million | +23.33% |
| 2023-12-31 | $77.06 Million | -20.52% |
| 2022-12-31 | $96.96 Million | +568.85% |
| 2021-12-31 | $14.50 Million | -86.65% |
| 2020-12-31 | $108.62 Million | +758.05% |
| 2019-12-31 | $12.66 Million | -53.74% |
| 2018-12-31 | $27.37 Million | +1838.07% |
| 2017-12-31 | $1.41 Million | +56.51% |
| 2016-12-31 | $902.19K | -94.47% |
| 2015-12-31 | $16.30 Million | +39.95% |
| 2014-12-31 | $11.65 Million | +212.10% |
| 2013-12-31 | $3.73 Million | +5.87% |
| 2012-12-31 | $3.53 Million | -- |